Baby formula shortage will stretch on until late July, FDA chief says
‘My expectation is that within two months we should be beyond normal and with a plethora’
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The baby formula shortage in the US will likely not be resolved until late July, the head of the Food and Drug Administration (FDA) has said at a senate committee hearing.
FDA chief Robert Califf told senators on Thursday that the shortage could end in two months, adding there will eventually be a surplus.
“I can’t be exact about this but my expectation is that within two months we should be beyond normal and with a plethora,” Mr Califf said.
He said the situation is going to get “better and better” with the current measures being taken.
The current formula shortage in the US is largely due to problems at Abbott Nutrition’s Michigan plant, the largest in the US, which was shut down by the FDA in February due to contamination.
The federal agency began narrowing down on problems at the plant after tracking four bacterial infections in infants who had allegedly been given formula from the facility.
Four infants have been hospitalised while two died after getting infected with the bacteria.
After detecting samples of bacteria in multiple parts of the facility, the FDA shut the Abbott plant and the company announced a large-scale recall of its formula on 17 February.
The federal agency, however, has not been able to conclusively link the bacteria found at the Abbott’s plant to those found in the babies.
Plans to inspect the plant were slowed by Covid, scheduling conflicts and other logistical problems, leading to the overall shortage of baby formula across the country, Mr Califf said.
Abbott Nutrition has yet to meet the FDA’s requirements and won’t be ready to open for several weeks, he added.
“I think Abbott would agree with us that they’re not ready to open. They had to replace the roofs, replace the floors, and they’re still not done. You just can’t reopen a plant with bacteria growing in it,” Mr Califf said.
In a statement, Abbott Nutrition said it was “working to address the FDA’s observations” and plans to restart operations on 4 June.
The FDA chief added there should be discussions on whether the federal government should create a national stockpile of formula “as a backup” to guard against future disruptions.
“I think we’re going to have to have a surplus. We’re certainly planning to have a surplus. The question is, should we maintain that surplus as a government activity for the foreseeable future?” he asked at the hearing.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments